Compare ANIK & UPXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANIK | UPXI |
|---|---|---|
| Founded | 1983 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.8M | 135.9M |
| IPO Year | 1993 | 2021 |
| Metric | ANIK | UPXI |
|---|---|---|
| Price | $9.54 | $2.27 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $16.00 | $6.00 |
| AVG Volume (30 Days) | 154.0K | ★ 4.3M |
| Earning Date | 11-05-2025 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.85 |
| Revenue | ★ $112,806,000.00 | $20,694,575.00 |
| Revenue This Year | N/A | $145.75 |
| Revenue Next Year | $4.79 | $12.88 |
| P/E Ratio | ★ N/A | $1.20 |
| Revenue Growth | ★ 30.55 | N/A |
| 52 Week Low | $7.87 | $1.67 |
| 52 Week High | $18.37 | $22.57 |
| Indicator | ANIK | UPXI |
|---|---|---|
| Relative Strength Index (RSI) | 49.43 | 49.33 |
| Support Level | $9.31 | $1.97 |
| Resistance Level | $9.85 | $2.33 |
| Average True Range (ATR) | 0.20 | 0.20 |
| MACD | 0.00 | 0.10 |
| Stochastic Oscillator | 43.12 | 78.29 |
Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States and also has its presence in Europe and Other countries.
Upexi Inc specializes in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space via Solana. Geographically, the company generates the majority of its revenue from the United States.